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Approximately 200 000 women were diagnosed with cancer
of the body of the uterus around the world each year at the
turn of the century. More than two-thirds of this estimated
total arise in developed countries, where age-standardised
incidence is four times higher than in developing countries
(Ferlay et al, 2004).
In the late 1990s, there were around 5300 new cases a year of
uterine cancer in England and Wales. It is the fifth most common
cancer in women, accounting for 3.5% of all cases. Age-
standardised incidence remained stable during the 1970s
and 1980s, but it has risen by 25% since 1990 (Parkin et al,
2001; Quinn et al, 2001). Annual incidence in five deprivation
groups defined by the woman’s small area of residence at diagnosis
ranged between 14 and 17 per 100 000 per year in the late
1990s, but there is no simple gradient across the groups, and
incidence rose at a similar rate in all socioeconomic groups (data
not shown). Mortality from uterine cancer has been declining
steadily in all age groups except the very elderly (Quinn et al,
2001).
Women whose uterus has been removed are no longer at risk,
and retaining them in the population denominators when
estimating incidence rates artificially reduces the estimates. The
prevalence of hysterectomy should be borne in mind when
interpreting incidence rates and trends. In 1995, 2.3 million
women in England and Wales had had a hysterectomy, with a peak
prevalence of 21% in the age group of 55– 59 years (Redburn and
Murphy, 2001), so the estimated 25% rise in overall incidence since
1990 may be an underestimate of the increase.
Diagnosis of endometrial cancer may arise from postmeno-
pausal bleeding, or irregular or heavy perimenopausal bleeding. If
detected early, both endometrial carcinoma and in situ malig-
nancy, which carries a high risk of progression to invasive cancer,
are mostly curable. The mainstay of treatment is total hyster-
ectomy, with or without removal of the ovaries, with external beam
radiotherapy in some cases. Well-differentiated tumours with
minimal invasion may be treated by brachytherapy with intra-
vaginal irradiation.
Endometrial cancer shares some epidemiological features with
breast and ovarian cancers, such as a peak in incidence around the
menopause, and risk factors such as early menarche, low parity
and late menopause. The risk of uterine cancer is also increased
among women treated with tamoxifen for breast cancer.
The unusual pattern of human carcinogenicity of tamoxifen has
been summarised as follows: ‘There is sufficient evidence in
humans for the carcinogenicity of tamoxifen in increasing the
risk for endometrial cancer and there is conclusive evidence
that tamoxifen reduces the risk for contralateral breast
cancer in women with a previous diagnosis of breast cancer’
(IARC, 1996).
The survival analyses reported here involve more than 53 000
women aged 15–99 years who were registered with uterine cancer
in England and Wales during the 14-year period 1986–1999,
87% of those who were eligible. Approximately 2% of women
were excluded because their vital status was unknown on 5
November 2002 when the data were extracted for analysis;
5% because they had previously had a primary malignancy of
another organ at some time since 1971, and a further 6%
because their duration of survival was zero or unknown. The
proportion excluded for zero or unknown duration of survival was
similar in all deprivation categories, and did not change during the
1990s.
Cancers of the uterus are not normally registered without
sufficient information being available for the cancer registry
to assign the anatomic location as either the cervix or corpus
uteri, but approximately 6% of tumours diagnosed in England
and Wales during 1986–1999 had been assigned a non-specific
anatomic site code (ICD-9 179, ICD-10 C55: malignant neoplasm
of uterus, part unspecified); these tumours were considered
ineligible for analysis.
More than half the tumours (58%) were coded as
adenocarcinoma, 15% as endometrioid carcinoma, and
almost 3% as leiomyosarcoma; 12% were poorly specified
carcinomas.
SURVIVAL TRENDS
Relative survival at both 1 and 5 years after diagnosis rose steadily
and significantly from 85 and 72%, respectively, in the late 1980s,
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to 88 and 76% in the late 1990s. This represents a deprivation-
adjusted rise of 2.5% every 5 years in short-term and longer-term
survival (Table 1). The increase in 5-year survival was more
marked between the early and late 1990s (Figure 1).
Short-term predictions suggest that these steady upward trends
are likely to continue, with predicted survival of 90% at 1 year and
77% at 5 years, based on hybrid analysis (Brenner and Rachet,
2004) of survival probabilities observed during 2000–2001
(Table 1).
DEPRIVATION
The deprivation gap in survival between the most affluent and the
most deprived groups is approximately 4%. This is a smaller gap in
survival than for some other common cancers in women, but
survival has nevertheless been consistently and significantly lower
for women living in more deprived areas.
The deprivation gap widened slightly but not significantly from
approximately 3% for women diagnosed in the late 1980s to
Table 1 Trends in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Women 84.5 (83.9, 85.1) 85.9 (85.3, 86.4) 88.1 (87.5, 88.6) 2.5** (1.4, 3.6) 89.3 (88.5, 90.1)
5 years Women 72.0 (71.2, 72.8) 72.7 (72.0, 73.5) 75.8 (74.8, 76.7) 2.5** (0.9, 4.1) 76.8 (75.6, 77.9)
10 years Women 68.8 (67.8, 69.7) 69.9 (68.9, 70.8) 0.7 (2.7, 4.0) 74.1 (72.8, 75.4)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival
estimated with cohort or complete approach (1986–1990, 1991–1995,
1996–1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001.
Table 2 Trends in the deprivation gap in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Women 2.5** (4.2, 0.8) 1.3 (2.9, 0.3) 3.9** (5.5, 2.3) 0.8 (2.0, 0.5) 3.2** (5.4, 1.0)
5 years Women 2.7* (5.1, 0.4) 3.5** (5.7, 1.2) 4.2** (6.9, 1.6) 0.8 (2.7, 1.1) 2.6 (5.9, 0.6)
10 years Women 3.5** (6.2, 0.9) 3.2* (6.0, 0.4) 0.3 (3.5, 4.2) 2.5 (6.4, 1.4)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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approximately 4% for those diagnosed in the late 1990s (Table 2
and Figure 2).
Predictions based on hybrid analysis of survival probab-
ilities observed during 2000–2001 suggest that the deprivation
gap for both short-term and longer-term survival is unlikely to
change markedly within the next 5 –10 years (Table 2).
COMMENT
Survival from uterine cancer in England and Wales is amongst the
highest for any cancer in women, after melanoma of the skin, and
close to that for breast cancer. Survival has improved steadily
in the 15 years up to 2001, and especially during the 1990s.
Although survival has improved in all socioeconomic groups, the
deprivation gap in survival between women in the most affluent
and the most deprived groups has not narrowed; if anything, the
data suggest that it widened slightly during the late 1990s.
Survival is closely related to stage at diagnosis, and the presenting
symptom of postmenopausal bleeding in 90% of women leads to
early diagnosis in the great majority. The very high survival in early-
stage disease suggests that even greater attention could be given to
encouraging early presentation, and to rapid referral, particularly
for women in deprived socioeconomic groups.
In the early 1990s, relative survival from uterine cancer at 5
years ranged from 60 to 84% in the 22 European countries
contributing to the EUROCARE-3 study. The age-adjusted
European average 5-year survival of 76% was 2– 3% higher than
in England and 6% higher than in Wales (Sant et al, 2003).
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